Related Experiment Video
Updated: Aug 12, 2026

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
Targeted therapy and pharmacogenomic programs
1Division of Oncology, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, California 90033, USA.
Abstract:
The goal in administering chemotherapeutics is to develop the ability to predict the outcome of therapy in terms of response and toxicity. Technology has been developed to allow tumor profiling with measurement of protein expression, gene expression levels of markers, and even genetic polymorphisms, which may predict response to particular chemotherapeutics. The chemotherapeutics for which particular markers have been shown to predict outcome include the fluoropyrimidines and platinums. The next step is to develop clinical trials that will assess prospectively the benefits of profiling a patient's particular tumor, which should translate into an improvement in response and toxicity.
Insights
Predicting chemotherapy response and toxicity is crucial. Tumor profiling, including genetic markers, shows promise for personalizing treatments with fluoropyrimidines and platinums, guiding future clinical trials.
Area of Science:
- Oncology
- Pharmacogenomics
Background:
- Chemotherapy aims to predict patient response and treatment toxicity.
- Tumor profiling technologies measure protein expression, gene expression, and genetic polymorphisms.
- These markers can predict patient response to specific chemotherapeutics.
Purpose of the Study:
- To explore the potential of tumor profiling in predicting chemotherapy outcomes.
- To identify specific chemotherapeutics, like fluoropyrimidines and platinums, where marker-based prediction is feasible.
Main Methods:
- Utilizing advanced technology for comprehensive tumor profiling.
- Measuring protein expression, gene expression levels, and genetic polymorphisms.
- Correlating molecular profiles with patient response and toxicity data.
Main Results:
- Established markers can predict treatment outcomes for fluoropyrimidines and platinums.
- Tumor profiling demonstrates potential for personalized chemotherapy selection.
Conclusions:
- Prospective clinical trials are necessary to validate the benefits of tumor profiling.
- Personalized profiling is expected to improve chemotherapy response rates and reduce toxicity.
More Related Videos
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Pharmacogenomics: Identification of New Drug Targets